Posted On: 11/17/2014 8:05:11 PM
Post# of 30066
If we only had Lympro and nothing else in the pipeline, we'd still be trading pretty close to where we are today. If we had all the other drugs, MANF, Elto, ESS, Phenoguard, but didn't have LymPro....we'd be trading at .03 cents, IMHO. That is how much emphasis I believe the market places on drugs that bring in revenue or are about to.
Tomorrow morning Gerald must reconcile his statement that Lympro would get a "significant portion" of the 150 million RUO market in 2015 with Jason's recent estimate we'd only get 1 million in 2015. Reconciling this revenue discrepancy tomorrow and giving us a little more specific revenue guidance for LymPro in 2015 is the only thing that will move our pps upward.
As nice as ESS is down the road for us....it will do nada for our pps prior to the up list. However, after the up list when institutions are looking to invest in AMBS, having this new drug to diversify our pipeline may bode well for us. So it does have near term value, but indirectly.
Tomorrow morning Gerald must reconcile his statement that Lympro would get a "significant portion" of the 150 million RUO market in 2015 with Jason's recent estimate we'd only get 1 million in 2015. Reconciling this revenue discrepancy tomorrow and giving us a little more specific revenue guidance for LymPro in 2015 is the only thing that will move our pps upward.
As nice as ESS is down the road for us....it will do nada for our pps prior to the up list. However, after the up list when institutions are looking to invest in AMBS, having this new drug to diversify our pipeline may bode well for us. So it does have near term value, but indirectly.
(0)
(0)
